Holen Sie sich die Stockscreener-App
27.11
1.35%
0.37
Schlusskurs vom Vortag:
$26.74
Offen:
$26.98
24-Stunden-Volumen:
862.28K
Relative Volume:
0.20
Marktkapitalisierung:
$20.13B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-84.72
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
-3.25%
1M Leistung:
+27.35%
6M Leistung:
+21.20%
1J Leistung:
+153.51%
1-Tages-Spanne:
$26.78
$27.69
1-Wochen-Bereich:
$26.50
$29.07
52-Wochen-Spanne:
$8.88
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
27.10 | 20.39B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.79 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.93 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
344.41 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
604.34 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.43 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser
Summit Therapeutics Inc. recovery potential after sell offConsistent Return Setup with Exit Strategy - Newser
Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser
Is Summit Therapeutics Inc. stock a growth or value playFree Day Trading Signals With High Precision - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser
Why is Summit Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com
Summit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Ivonescimab's Dual-Action Revolution: A Catalyst for Akeso and Summit Therapeutics in the $500M+ Lung Cancer Market - AInvest
Does Summit Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - jammulinksnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Is Summit Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike Monitors - Newser
When is Summit Therapeutics Inc. stock expected to show significant growthAchieve consistent profits with proven strategies - jammulinksnews.com
Summit Therapeutics Jumps 4% As Technicals Signal Bullish Breakout Potential - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Summit Therapeutics Soars 4.64%—Could This Biotech Breakthrough Signal a Game-Changer? - AInvest
What drives Summit Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bank of New York Mellon Corp Has $6.57 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Will Summit Therapeutics Inc. stock benefit from AI tech trendsTriple-digit growth rates - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Summit Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.26%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):